NO970309L - Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri - Google Patents

Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri

Info

Publication number
NO970309L
NO970309L NO970309A NO970309A NO970309L NO 970309 L NO970309 L NO 970309L NO 970309 A NO970309 A NO 970309A NO 970309 A NO970309 A NO 970309A NO 970309 L NO970309 L NO 970309L
Authority
NO
Norway
Prior art keywords
progestagen
endometriosis
treatment
progesterone antagonist
leiomyomata uteri
Prior art date
Application number
NO970309A
Other languages
English (en)
Other versions
NO970309D0 (no
Inventor
Klaus Stoeckemann
Kristof Chwalisz
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag filed Critical Schering Ag
Publication of NO970309L publication Critical patent/NO970309L/no
Publication of NO970309D0 publication Critical patent/NO970309D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Secondary Cells (AREA)
  • Fuel Cell (AREA)
  • Primary Cells (AREA)

Abstract

Foreliggende oppfinnelse gjelder anvendelsen av et produkt som i kombinasjon inneholder enkelte doser- ingsenheter av en konkurrerende proges- teronantagonist og enkelte doseringsen- heter av et gestagen som skal admini- streres oralt i sekvens, hvori hver enkelt doseringsenhet som inneholder den konkurrerende progesteronantagon- ist, inneholder denne i en ikke-abort- utløsende mengde, for fremstilling av et legemiddel for behandling av endo- metriose eller Leiomyomata uteri.
NO970309A 1994-07-27 1997-01-24 Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri NO970309D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4426601A DE4426601A1 (de) 1994-07-27 1994-07-27 Verwendung eines Kombinationsproduktes enthaltend einen kompetitiven Progesteronantagonisten und ein Gestagen zur Herstellung eines Arzneimittels zur Behandlung der Endometriose oder des Leiomyomata uteri
PCT/EP1995/002998 WO1996003130A1 (de) 1994-07-27 1995-07-27 Progesteronantagonist und gestagen zur behandlung der endometriose und leiomyomata uteri

Publications (2)

Publication Number Publication Date
NO970309L true NO970309L (no) 1997-01-24
NO970309D0 NO970309D0 (no) 1997-01-24

Family

ID=6524269

Family Applications (1)

Application Number Title Priority Date Filing Date
NO970309A NO970309D0 (no) 1994-07-27 1997-01-24 Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri

Country Status (22)

Country Link
US (1) US6043234A (no)
EP (1) EP0772441B1 (no)
JP (1) JPH10502092A (no)
KR (1) KR100365879B1 (no)
CN (1) CN1124848C (no)
AT (1) ATE213417T1 (no)
AU (1) AU705618B2 (no)
CA (1) CA2195425C (no)
CZ (1) CZ292177B6 (no)
DE (2) DE4426601A1 (no)
DK (1) DK0772441T3 (no)
ES (1) ES2172592T3 (no)
FI (1) FI970260A0 (no)
HU (1) HU226453B1 (no)
IS (1) IS4407A (no)
MX (1) MX9700309A (no)
NO (1) NO970309D0 (no)
NZ (1) NZ291417A (no)
PL (1) PL318264A1 (no)
PT (1) PT772441E (no)
SK (1) SK10497A3 (no)
WO (1) WO1996003130A1 (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19531936A1 (de) * 1995-08-17 1997-02-20 Schering Ag Kombinationspräparat zur Kontrazeption, Kits diese enthaltend und eine Methode diese verwendend
TR200001334T2 (tr) 1997-11-14 2000-09-21 Akzo Nobel N.V. Progestojen-anti-progestojen rejimleri.
US6787531B1 (en) * 1999-08-31 2004-09-07 Schering Ag Pharmaceutical composition for use as a contraceptive
US20020132801A1 (en) * 2001-01-11 2002-09-19 Schering Aktiengesellschaft Drospirenone for hormone replacement therapy
JO2334B1 (en) * 2000-01-18 2006-06-28 باير شيرنغ فارما اكتنجيسيلشافت Drospirenone for hormone replacement therapy
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
US20080214512A1 (en) * 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
EP1977752A1 (de) * 2007-03-01 2008-10-08 Bayer Schering Pharma Aktiengesellschaft Pharmazeutische Zubereitung zur Verminderung der Endometriose
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
US20080306034A1 (en) * 2007-06-11 2008-12-11 Juneau Biosciences, Llc Method of Administering a Therapeutic
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
TWI477276B (zh) * 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen
DE102009034368A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylenphenyl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034366A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-methylenoxyalkylenaryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034367A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzyliden-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102009034362A1 (de) 2009-07-20 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034525A1 (de) 2009-07-21 2011-01-27 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
DE102009034526A1 (de) 2009-07-21 2011-02-10 Bayer Schering Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-ethinylphenyl-Derivate, Verfahren zu deren Herstellung und deren Verwendung zur Behandlung von Krankheiten
DE102010007722A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102010007719A1 (de) 2010-02-10 2011-08-11 Bayer Schering Pharma Aktiengesellschaft, 13353 Progesteronrezeptorantagonisten
DE102011004899A1 (de) 2011-03-01 2012-09-06 Bayer Pharma Aktiengesellschaft 17-Hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Behandlung von Krankheiten
WO2012121767A1 (en) * 2011-03-09 2012-09-13 Arstat, Inc. Treatment of uterine fibroids by intravaginal administration of a low dose of selective progesterone receptor modulator (sprm), anti-progestin, or anti-progestational agent
CA2872644A1 (en) 2012-05-31 2013-12-05 Allergan Pharmaceuticals International Limited Formulations and methods for vaginal delivery of antiprogestins
US9545411B2 (en) 2012-11-02 2017-01-17 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US20160296534A1 (en) 2013-04-11 2016-10-13 Bayer Pharma Aktiengesellschaft Progesterone receptor antagonist dosage form
US9096641B2 (en) * 2013-06-05 2015-08-04 Evestra, Inc. Imidazolyl progesterone antagonists
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
FR3078952B1 (fr) * 2018-03-16 2020-03-27 Arianegroup Sas Systeme de mise en orbite de travail pour un satellite

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore

Also Published As

Publication number Publication date
CN1154067A (zh) 1997-07-09
SK10497A3 (en) 1997-08-06
ATE213417T1 (de) 2002-03-15
JPH10502092A (ja) 1998-02-24
PL318264A1 (en) 1997-05-26
DE4426601A1 (de) 1996-02-01
DK0772441T3 (da) 2002-05-27
CZ292177B6 (cs) 2003-08-13
ES2172592T3 (es) 2002-10-01
KR970704450A (ko) 1997-09-06
CN1124848C (zh) 2003-10-22
FI970260L (fi) 1997-01-22
CZ20797A3 (en) 1997-05-14
KR100365879B1 (ko) 2003-03-10
DE59510069D1 (de) 2002-03-28
HUT77092A (hu) 1998-03-02
FI970260A7 (fi) 1997-01-22
IS4407A (is) 1997-01-02
AU705618B2 (en) 1999-05-27
HU226453B1 (en) 2008-12-29
FI970260A0 (fi) 1997-01-22
EP0772441A1 (de) 1997-05-14
MX9700309A (es) 1997-05-31
CA2195425A1 (en) 1996-02-08
US6043234A (en) 2000-03-28
EP0772441B1 (de) 2002-02-20
CA2195425C (en) 2008-03-11
AU3254395A (en) 1996-02-22
PT772441E (pt) 2002-08-30
NZ291417A (en) 1998-12-23
NO970309D0 (no) 1997-01-24
WO1996003130A1 (de) 1996-02-08

Similar Documents

Publication Publication Date Title
NO970309L (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
DK0735882T3 (da) Kombinationsprodukt til kontraception indeholdende progesteronantagonister og gestagen
PL323490A1 (en) Tetralinic compounds exibiting acitity against multgiple-drug refractoriness
UA37259C2 (uk) Активна речовина для одержання лікарських засобів при лікуванні дисфункціональних маткових кровотеч
ATE356635T1 (de) Verfahren zur vorbeugung oder behandlung von benignen gynäkologischen störungen
FI971742A7 (fi) Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskauden ehkäisyyn naisilla
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
SE9902597D0 (sv) New use
ES2348038T5 (es) Preparado polifásico para la contracepción sobre la base de un estrógeno natural
HUP0004461A2 (hu) Apoliprotein B kiválasztást/mikroszomális trigliceridtranszfer-proteint gátló anyag alkalmazása gyógyászati készítmények előállítására és a fenti gyógyászati készítmények
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
HUP9901935A2 (hu) Gyógyszerek és terápiás szerek és más glikozaminoglikánok (GAG) dózisainak célbajuttatására alkalmas dóziskészlet
RU96123161A (ru) Способ профилактики ранних рецидивов стенокардии и последствий респираторного дистресс-синдрома взрослых у больных, перенесших операцию аортокоронарного шунтирования
DE69827017D1 (de) Kombinationen von endometrium schonenden gestagenen und endometrium atrophisierenden gestagenen mit estrogenen, bei der oralen empfängnisverhütung
EA200701091A1 (ru) Противозачаточный фармацевтический препарат
Carey Side effects of oral contraceptives
TH61362A (th) องค์ประกอบทางเภสัชกรรม
BR9816142A (pt) Esteróides de 19-nor-colano como iniciadores neuroquìmicos de mudança na função hipotalâmica humana

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application